- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05375422
Effects of SARAH Protocol in Women With Rheumatoid Arthritis
March 19, 2026 updated by: Samira Tatiyama Miyamoto, PhD, Federal University of Espirito Santo
Effects of the Strengthening and Stretching Protocol for Rheumatoid Arthritis in the Hands (SARAH) on Hand Function in Women With Rheumatoid Arthritis
The aim of this study is to analyze the effect of the SARAH protocol, which is a set of exercises with components of muscle strengthening, range of motion gain and home exercises, combined with an educational intervention, on hand function in women with rheumatoid arthritis (RA).
Study Overview
Detailed Description
The volunteers will perform the SARAH protocol exercises (brazilian portuguese version) along with the usual guidelines.
To participate in the research, patients must be diagnosed with RA using disease-modifying antirheumatic medication for at least 3 months, and age equal to or older to 18 years.
Participants with incomplete elementary school and score <24 on the Mini-Mental State Examination Questionnaire (MMSE) will be excluded from the study.
The participants will be evaluated before and after the intervention regarding the variables: hand function (Michigan Hand Outcomes Questionnaire), pain (Brief Pain Inventory), handgrip strength (Jamar® manual dynamometer), quality of life (Euro Quality of Life Instrument-5D), functional capacity (Health Assessment Questionnaire), RA disease activity (DAS28).
The SARAH group will receive an exercise book containing 7 mobility exercises and 4 strength exercises that are performed using elastic materials that provide progressive degrees of resistance to movement.
Patients will be guided in person by a trained professional, so that they are carried out without their presence, in the home environment, daily and monitored at periodically scheduled meetings.
A total of 4 face-to-face meetings will be held during the 3-month follow-up.
The program will last 12 weeks, with 4 face-to-face meetings lasting 40 minutes and monitored in periodically scheduled meetings.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brazil, 29050-780
- Samira Tatiyama Miyamoto, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- patients must be diagnosed with RA
- using disease-modifying antirheumatic medication for at least 3 months
- over 18 years old
Exclusion Criteria:
- incomplete elementary school and score <24 on the Mini-Mental State Examination Questionnaire (MMSE)
- diagnosis of another associated autoimmune disease
- having undergone previous surgical procedures on the hands
- having suffered a fracture in the joints of the upper limbs in the last six months
- being a patient on the waiting list for orthopedic surgery of the upper limb
- being pregnant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: SARAH group
The SARAH group will receive an exercise book containing 7 mobility exercises and 4 strength exercises that are performed using elastic materials that provide progressive degrees of resistance to movement.
Patients will be guided in person by a trained professional, so that they are carried out without their presence, in the home environment, daily and monitored at periodically scheduled meetings.
A total of 4 face-to-face meetings will be held during the 3-month follow-up.
The SARAH group and the control group will receive information related to joint protection, use of splints, assistive devices and other general advice, as needed, will receive some booklets to reinforce the guidelines.
The program will last 12 weeks, with 4 face-to-face meetings lasting 40 minutes and monitored in periodically scheduled meetings.
|
Set of exercises with components of muscle strengthening, range of motion gain and home exercises.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hand function
Time Frame: 3 months
|
Michigan Hand Outcomes Questionnaire.
A total of 37 items assess six domains: general hand function, activities of daily living, work performance, pain, aesthetics, and patient satisfaction with hand function.
The participant must score each item using Likert-type scales ranging from 1 to 5.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain inventory
Time Frame: 3 months
|
Brief Pain Inventory.
It classifies pain as mild when scored from 1 to 4, moderate when scored from 5 to 7, and severe when the participant selects values from 8 to 10 points.
|
3 months
|
|
Hand grip strength
Time Frame: 3 months
|
Hand dynamometer.
The participant should press the dynamometer with maximum force for 3 seconds and rest for 60 seconds.
All values must be recorded for later calculation of the average of three attempts.
|
3 months
|
|
Healthy related quality of life
Time Frame: 3 months
|
Euro Quality of Life Instrument-5D (EQ-5D).
The questionnaire consists of questions about health and disease states, such as: mobility, personal care, usual activities, pain/discomfort, anxiety/depression, and each of these has three associated levels of severity, corresponding to no problems (level 1).
), some problems (level 2) and extreme problems (level 3) experienced or felt by the individual.
|
3 months
|
|
Functional capacity
Time Frame: 3 months
|
Health Assesment Questionnaire (HAQ).
Eight categories with scores from 0 (no problem) to 3 (unable to do) per category.
The score for each category appears at the highest number of any of its items, and the final HAQ score is the average of the scores for the eight categories.
|
3 months
|
|
Disease activity
Time Frame: 3 months
|
Disease Activity Score (DAS-28).
The DAS-28 score can be interpreted on a categorical scale: it is indicative of disease remission values <2.6, light activity when it has a result between 2.6 and 3.2, moderate activity when values >3.2 to 5, 1 and high disease activity when the result is greater than 5.1.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 7, 2022
Primary Completion (Actual)
May 7, 2022
Study Completion (Actual)
February 7, 2024
Study Registration Dates
First Submitted
May 11, 2022
First Submitted That Met QC Criteria
May 11, 2022
First Posted (Actual)
May 16, 2022
Study Record Updates
Last Update Posted (Actual)
March 23, 2026
Last Update Submitted That Met QC Criteria
March 19, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FUEspiritoSanto03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.